S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
GE   12.61 (-1.10%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
GE   12.61 (-1.10%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
GE   12.61 (-1.10%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
GE   12.61 (-1.10%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NASDAQ:CDXS - Codexis Stock Price, Forecast & News

$13.98
-0.16 (-1.13 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$13.94
Now: $13.98
$14.18
50-Day Range
$14.03
MA: $16.46
$18.60
52-Week Range
$12.68
Now: $13.98
$22.38
Volume248,524 shs
Average Volume371,061 shs
Market Capitalization$818.08 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.59 million
Book Value$1.04 per share

Profitability

Net Income$-10,880,000.00

Miscellaneous

Employees132
Market Cap$818.08 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.


Codexis (NASDAQ:CDXS) Frequently Asked Questions

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.01 EPS for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.10. The biotechnology company earned $21.91 million during the quarter, compared to analysts' expectations of $16.56 million. Codexis had a negative return on equity of 15.24% and a negative net margin of 17.85%. View Codexis' Earnings History.

When is Codexis' next earnings date?

Codexis is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Codexis.

What price target have analysts set for CDXS?

2 brokerages have issued twelve-month price objectives for Codexis' shares. Their forecasts range from $22.50 to $25.00. On average, they expect Codexis' share price to reach $23.75 in the next twelve months. This suggests a possible upside of 69.9% from the stock's current price. View Analyst Price Targets for Codexis.

What is the consensus analysts' recommendation for Codexis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.

Has Codexis been receiving favorable news coverage?

News stories about CDXS stock have trended neutral recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Codexis earned a daily sentiment score of 0.1 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Codexis.

Are investors shorting Codexis?

Codexis saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,410,000 shares, an increase of 8.4% from the January 15th total of 4,990,000 shares. Based on an average daily trading volume, of 335,000 shares, the short-interest ratio is presently 16.1 days. Approximately 10.1% of the company's shares are sold short. View Codexis' Current Options Chain.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Canopy Growth (CGC), AbbVie (ABBV), Antares Pharma (ATRS), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP), Cisco Systems (CSCO), Xilinx (XLNX) and AT&T (T).

Who are Codexis' key executives?

Codexis' management team includes the folowing people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 55)
  • Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
  • Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
  • Ms. Laurie Heilmann, Sr. VP of Bus. Devel. & Marketing
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 73)

Who are Codexis' major shareholders?

Codexis' stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (6.47%), William Blair Investment Management LLC (2.96%), Janus Henderson Group PLC (2.57%), Nikko Asset Management Americas Inc. (2.35%), Sumitomo Mitsui Trust Holdings Inc. (2.35%) and FMR LLC (2.33%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Institutional Ownership Trends for Codexis.

Which institutional investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Prescott Group Capital Management L.L.C., FMR LLC, Oak Ridge Investments LLC, Stifel Financial Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Bank of America Corp DE. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols and Thomas R Baruch. View Insider Buying and Selling for Codexis.

Which institutional investors are buying Codexis stock?

CDXS stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Baillie Gifford & Co., Janus Henderson Group PLC, Aviva PLC, Essex Investment Management Co. LLC, Goldman Sachs Group Inc., Barclays PLC and Marshall Wace LLP. Company insiders that have bought Codexis stock in the last two years include John J Nicols and Patrick Y Yang. View Insider Buying and Selling for Codexis.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $13.98.

How big of a company is Codexis?

Codexis has a market capitalization of $817.82 million and generates $60.59 million in revenue each year. The biotechnology company earns $-10,880,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.View Additional Information About Codexis.

What is Codexis' official website?

The official website for Codexis is http://www.codexis.com/.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]


MarketBeat Community Rating for Codexis (NASDAQ CDXS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  311 (Vote Underperform)
Total Votes:  614
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel